A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.

Placebo (saline) will be administered subcutaneously once daily.